Daily Sepsis Research Analysis
Analyzed 50 papers and selected 3 impactful papers.
Summary
The most impactful papers highlight a shift toward biologically informed and context-specific sepsis care. Mechanistic studies identify mitochondrial reverse electron transfer and lactylation as potential therapeutic targets, while an international Delphi consensus emphasizes physiology-guided management, rapid source control, antimicrobial stewardship, and individualized hemodynamic support.
Research Themes
- Mitochondrial mechanisms and targeted therapy in sepsis-induced cardiomyopathy
- Lactate-driven epigenetic regulation and immune-metabolic crosstalk
- International consensus, precision management, and antimicrobial stewardship
Selected Articles
1. Metformin Attenuates Sepsis-Induced Cardiomyopathy via Inhibition of Reverse Electron Transfer at Mitochondrial Complex I.
Using lipopolysaccharide-stimulated H9C2 cardiomyocytes and a cecal ligation and puncture rat model, the study links septic myocardial injury to succinate accumulation, elevated mitochondrial membrane potential, and excessive reactive oxygen species generated by reverse electron transfer at complex I. Metformin inhibited this mitochondrial process and attenuated cardiac injury, identifying a clinically available drug as a potential mechanism-based therapy for sepsis-induced cardiomyopathy.
Impact: This study identifies a specific and pharmacologically targetable mitochondrial mechanism in sepsis-induced cardiomyopathy rather than treating myocardial dysfunction as nonspecific inflammatory injury. Because metformin is already clinically used, the findings provide a plausible translational pathway for repurposing, although clinical efficacy remains unproven.
Clinical Implications: Metformin or related inhibitors of mitochondrial complex I may warrant investigation as adjunctive therapy for sepsis-induced cardiomyopathy, particularly in patients with evidence of mitochondrial redox stress. The results do not support off-label clinical use because the evidence is currently limited to cellular and animal models.
Key Findings
- Septic myocardial injury was associated with succinate accumulation, elevated mitochondrial membrane potential, and reverse electron transfer at mitochondrial complex I.
- Reverse electron transfer increased mitochondrial reactive oxygen species and contributed to cardiomyocyte injury in vitro and in vivo.
- Metformin attenuated mitochondrial injury and sepsis-induced cardiac dysfunction by inhibiting this process.
Methodological Strengths
- The mechanism was examined in both cultured cardiomyocytes and a polymicrobial sepsis animal model.
- The study connected biochemical mitochondrial abnormalities with cardiac injury and tested a clinically available pharmacologic intervention.
Limitations
- The evidence is preclinical and does not establish safety, optimal dosing, or clinical efficacy in patients with sepsis.
- The H9C2 cell line and animal model may not reproduce the biological heterogeneity of human sepsis-induced cardiomyopathy.
Future Directions: Future studies should validate reverse electron transfer biomarkers in patients, determine whether metformin benefits specific cardiometabolic phenotypes, and conduct carefully designed early-phase clinical trials with cardiac and patient-centered outcomes.
Sepsis-induced cardiomyopathy (SICM) is a life-threatening complication of sepsis; however, its molecular mechanisms remain incompletely understood, which has hindered the development of targeted therapies. We hypothesized that excessive mitochondrial reactive oxygen species (mtROS) production through reverse electron transfer (RET) at mitochondrial complex I contributes to septic myocardial injury and that metformin, a clinically used inhibitor of mitochondrial complex I, protects the myocardium by inhibiting this process. In lipopolysaccharide-stimulated H9C2 cardiomyocytes and cecal ligation and puncture-induced septic rats, sepsis was characterized by an elevated mitochondrial membrane potential, accompanied by succinate accumulation, an increased NADH/N
2. Lactate and lactylation in sepsis: regulation of immune-metabolic crosstalk and organ injury.
This review reframes lactate in sepsis from a marker of hypoperfusion to a metabolic and epigenetic mediator. It synthesizes evidence that lysine lactylation regulates macrophage polarization, trained immunity, neutrophil extracellular trap formation, T-cell dysfunction, and organ-specific injury, with effects that may be protective or pathogenic depending on cell type and tissue context.
Impact: The paper integrates immunometabolism with epigenetic regulation and explains why lactate-directed therapies may have divergent effects across organs. This framework could guide biomarker-enriched and cell-type-specific therapeutic strategies rather than nonspecific lactate reduction.
Clinical Implications: Lactate should be interpreted as both a severity marker and a potential mediator of disease biology. Lactylation-related biomarkers or enzymes may eventually support patient stratification, but therapeutic inhibition or enhancement requires organ- and cell-specific validation before clinical implementation.
Key Findings
- Sepsis-associated lactate accumulation can drive histone and non-histone lysine lactylation rather than merely reflecting tissue hypoxia.
- Lactylation effects are context dependent: the same mark, including H3K18la, may be protective in macrophages but pathogenic in alveolar or tubular epithelial cells.
- Lactylation may regulate macrophage polarization, trained immunity, neutrophil extracellular trap formation, T-cell dysfunction, and injury of the lung, heart, kidney, and vasculature.
Methodological Strengths
- The review integrates metabolic, epigenetic, immunologic, and organ-specific evidence across multiple stages of sepsis.
- It distinguishes validated lactylation writers and erasers from candidates that still require experimental validation.
Limitations
- The article is a review and therefore its conclusions depend on the quality, heterogeneity, and completeness of the underlying studies.
- Several proposed writers, erasers, substrates, and therapeutic strategies remain unvalidated in sepsis models or humans.
Future Directions: Research should establish longitudinal and cell-type-resolved lactylation maps, validate circulating or tissue biomarkers, and test precision interventions that account for disease phase, organ, and immune phenotype.
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and remains a leading cause of death worldwide. Hyperlactatemia, a hallmark metabolic disorder in sepsis, has recently been recognized as an epigenetic modulator via lysine lactylation. This Review synthesizes the evolving understanding of lactate-from a prognostic biomarker to a pathogenic mediator and, most recently, to an epigenetic modulator through lysine lactylation (Kla). Sepsis induces persistent Warburg-like glycolytic reprogramming in immune and parenchymal cells, generating lactate that not only serves as a metabolic fuel but also accumulates to drive covalent histone and non-histone Kla. Rather than merely indicating tissue hypoxia, this lactate surge directly remodels transcriptional and metabolic programs via both lactyl-CoA-dependent
3. International multidisciplinary consensus statement on sepsis code guidelines: A Delphi approach.
This multinational modified Delphi study included 164 experts from 22 countries and achieved consensus on 40 statements spanning recognition, diagnostics, source control, antimicrobials, monitoring, and hemodynamic management. Strong agreement favored structured sepsis programs, NEWS-2 for early recognition, urgent source control within 6 hours, rapid molecular diagnostics linked to stewardship, norepinephrine as first-line vasopressor, pharmacokinetic/pharmacodynamic antibiotic dosing, and dynamic fluid assessment.
Impact: The study translates international multidisciplinary expertise into operational guidance for sepsis-code programs and explicitly identifies areas where consensus is absent. Its emphasis on dynamic fluids, timely source control, stewardship, and avoidance of universal therapies may help reduce rigid protocol-driven care.
Clinical Implications: Hospitals may use these statements to develop or refine sepsis-response systems, prioritize urgent source control, integrate rapid diagnostics with antimicrobial stewardship, use norepinephrine as the usual first-line vasopressor, and individualize fluid administration. The recommendations should complement, not replace, patient-level assessment and local microbiologic and resource considerations.
Key Findings
- A modified Delphi process involving 164 experts from 22 countries achieved consensus on 40 sepsis-management statements.
- Strong endorsement was obtained for structured hospital sepsis programs, NEWS-2, adjunctive biomarker use, urgent source control within 6 hours, rapid molecular diagnostics, and norepinephrine as first-line vasopressor.
- No consensus was reached on routine reliance on Sepsis-2, Sepsis-3, or qSOFA, high mean arterial pressure targets, or universal combination antimicrobial therapy.
Methodological Strengths
- The panel was multinational and multidisciplinary, with experts from 22 countries, 12 specialties, and 105 scientific societies.
- Three iterative rounds and a prespecified consensus threshold of at least 70% provided a transparent process for resolving controversial issues.
Limitations
- Delphi consensus reflects expert judgment and cannot establish comparative treatment efficacy or causal clinical benefit.
- Representation, local resources, and healthcare-system differences may limit generalizability despite the international panel.
Future Directions: The consensus statements should be prospectively evaluated through implementation studies and pragmatic trials that measure adherence, time to source control, antimicrobial exposure, organ-support outcomes, survival, and recovery. Future updates should incorporate data from low-resource settings and phenotype-enriched strategies.
BACKGROUND: Sepsis remains a major global health challenge. International guidelines exist, but their implementation is inconsistent, and supporting evidence largely comes from high-income settings. The objective of this study was to generate international, multidisciplinary expert consensus on controversial aspects of sepsis management within the framework of sepsis code programs. METHODS: A multinational modified Delphi study was conducted with 164 experts from 22 countries, 12 specialties, and 105 scientific societies. Seven domains were evaluated: early diagnosis, biomarkers, diagnostic microbiology, hemodynamic monitoring, source control, antimicrobial therapy, and hemodynamic management. Consensus was defined as ≥70% agreement across three iterative rounds using Likert scales (Rounds 1-2) and binary format (Round 3). RESULTS: Consensus was achieved for 40 statements. Strong endorsement (82%-95%) was reached for structured hospital sepsis programs, NEWS-2 as the preferred early recognition tool, biomarker use (notably procalcitonin) to complement clinical assessment, urgent source control within 6 h independent of hemodynamic status, rapid molecular diagnostics integrated with antimicrobial stewardship, and norepinephrine as first-line vasopressor therapy.